Aviva PLC Acquires 20,073 Shares of Edwards Lifesciences Co. (NYSE:EW)

Aviva PLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 797,915 shares of the medical research company's stock after buying an additional 20,073 shares during the period. Aviva PLC owned 0.14% of Edwards Lifesciences worth $59,070,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of EW. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. State Street Corp boosted its holdings in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock valued at $1,733,270,000 after purchasing an additional 256,538 shares during the period. Geode Capital Management LLC grew its position in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in shares of Edwards Lifesciences by 7.7% during the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Truist Financial dropped their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $79.81.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,853 shares of company stock worth $4,534,247. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.2 %

NYSE:EW traded up $0.15 during midday trading on Friday, reaching $68.41. 1,252,832 shares of the stock traded hands, compared to its average volume of 4,883,516. The stock has a market capitalization of $40.21 billion, a P/E ratio of 9.79, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a fifty day moving average of $71.36 and a 200 day moving average of $70.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.